News

FDA approves Monjuvi for relapsed, refractory follicular lymphoma
The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...
MPR23h
Monjuvi Approved for Relapsed/Refractory Follicular Lymphoma
The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...
Cancer Therapy Advisor1d
Tafasitamab Combo May Be New Standard for Rel/Ref Follicular Lymphoma
Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.
Science Daily1y
How virus causes cancer: Potential treatment
The research points to effective new treatment options for KSHV-associated cancers, including Kaposi's sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease.
rarediseaseadvisor1y
Primary Central Nervous System Lymphoma (PCNSL)
Primary CNS Burkitt Lymphoma Primary CNS Burkitt lymphoma (PCNSBL) is very rare, affecting individuals from 6 months to 75 years old. Only 38 cases of PCNSBL have been documented, according to a study ...
The American Journal of Managed Care1y
Despite Novelty, Fluid Overload–Associated LBCL Has Distinguishing Features
“Historically, this presentation has been associated with primary effusion lymphoma (PEL), a human herpesvirus 8 (HHV8)–positive B-cell lymphoma with a predilection for patients that are ...
The American Journal of Managed Care3y
Review Highlights Progress and Challenges in Treating HIV/AIDS-Associated Lymphoma
plasmablastic lymphoma, and primary effusion lymphoma (PEL). PEL is caused by HHV8, or Kaposi sarcoma-associated herpesvirus (KSHV). HL is one of the most prevalent non-AIDS-defining cancers ...
Frontiers4y
Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas
diffuse large B-cell lymphoma, and primary effusion lymphoma. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most common NHL in the United States and responsible for ...
Too Old to Operate4y
Induction of apoptosis by Shikonin through ROS-mediated intrinsic and extrinsic apoptotic pathways in primary effusion lymphoma.
Primary effusion lymphoma (PEL) is an incurable non-Hodgkin’s lymphoma and novel biology-based treatments are urgently needed in clinical settings. Shikonin (SHK), a napthoquinone derivative, has been ...
Too Old to Operate5y
Clinicopathologic characteristics and survival of patients with primary effusion lymphoma.
Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma confined to body cavities and universally associated with human herpesvirus type 8 infection. The prognosis of this entity remains poor ...
casereports.bmj5y
Extracavitary primary effusion lymphoma recurring with syphilis in an HIV-infected patient
A 59-year-old Caucasian man infected with HIV, in remission from human herpes virus-8-positive extracavitary primary effusion lymphoma (EC-PEL), presented to a sexual health clinic with fever and ...